Monopar Therapeutics (NASDAQ:MNPR) Director Sells $214,755.70 in Stock

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $68.35, for a total transaction of $214,755.70. Following the transaction, the director owned 5,373 shares in the company, valued at approximately $367,244.55. This trade represents a 36.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Anderson also recently made the following trade(s):

• On Tuesday, August 25th, Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock. The stock was sold at an average price of $111.77, for a total transaction of $351,181.34.

Monopar Therapeutics Price Performance

Shares of NASDAQ:MNPR traded up $2.92 during mid-day trading on Wednesday, reaching $72.81. The stock had a trading volume of 189,611 shares, compared to its average volume of 143,006. Monopar Therapeutics Inc. has a 1 year low of $50.07 and a 1 year high of $124.82. The business’s 50 day moving average price is $88.66 and its 200 day moving average price is $77.40.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. On average, equities research analysts forecast that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp purchased a new position in Monopar Therapeutics during the second quarter worth $7,124,000. Bank of America Corp DE increased its position in Monopar Therapeutics by 838.2% during the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC increased its position in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after acquiring an additional 30,370 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Monopar Therapeutics in the first quarter valued at $250,000. Finally, Siren L.L.C. raised its stake in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares during the period. 1.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on MNPR shares. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Morgan Stanley reissued an “overweight” rating and issued a $130.00 target price on shares of Monopar Therapeutics in a report on Monday, August 17th. Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright increased their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.00.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.